Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial

Table 5 Adverse events in 12 weeks

Adverse events	Azithromycin	Placebo	p-value
Gastro-intestinal*, n (%)	5 (11.9)	6 (14.3)	0.75
Upper respiratory †, n (%)	7 (16.7)	8 (19.0)	0.78
Cardiovascular ‡, n (%)	2 (4.8)	1 (2.4)	0.56
Other§, n (%)	3 (7.1)	5 (11.9)	0.71

*gastro-intestinal adverse events were diarrhoea, nausea and ulcus ventriculi.
†Upper respiratory adverse events were common cold, dyspnoea and cough.
‡Cardiovascular adverse events: myocardial infarction, supraventricular tachycardia, heart failure.
§Other include: pruritis, headache, disturbance of taste, malaise, atralgia and hyperhidrosis.

ISSN: 1465-993X